Follow
About Nate
While earning a degree in Mathematics from U.C. Berkeley in the early 1990s, Nate Pile also started his investment career following biotech stocks while working for legendary biotech investor and analyst Jim McCamant. He launched his own newsletter, Nate's Notes, 1995 with an eye towards helping individual investors grow their wealth through a common sense, long-term approach to investing, and in the 23 years since, the newsletter has quietly become one of the top-performing newsletters in the industry.
Nate's Articles
It has been another good four weeks not just for the market as a whole, but for both of the newsletter's portfolios as well. I like the abrdn Life Sciences Investors (HQL) fund here, writes Nate Pile, editor of Nate’s Notes.
I am once again making MannKind (MNKD) my Top Pick for the coming year. The company's lead product is Afrezza, an inhalable form of insulin for both Type 1 and Type 2 diabetics, writes Nate Pile, editor of Nate’s Notes.
Charles Schwab's (SCHW) stock got crushed last March as part of the across-the-board selloff we saw in regional bank stocks. While the stock has managed to rally nicely off the lows set during that turbulent time period, I believe it is still being undervalued by the market, opines Nate Pile, editor of Nate’s Notes.
September was another rough month for stocks overall and an especially brutal month for regional banking and utility stocks. But once the fever breaks, interest rates will finally level off and perhaps even tick down a bit, and stocks will also start to find their footing again. I like Runway Growth Finance Corp. (RWAY) here, writes Nate Pile, editor of The Little River Investment Guide.
Newsletter Contributions
Nate's Notes
Since 1995, Editor Nate Pile has been sharing his ideas about the stock market and investing with individual investors around the world… and over the course of the past 25 years, his flagship newsletter (Nate’s Notes) has quietly become one of the top performing investment newsletters in the country.
Learn More